Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

First-of-its-Kind Digital Therapeutic BNT200 Discovered

Blue Note Therapeutics discovered first-of-its-kind prescription-only digital therapeutic BNT200 for the treatment of anxiety and depressive symptoms in adults patients with acute myeloid leukemia (AML) hospitalised for a regimen of high-intensity induction chemotherapy.

BNT200 is a software as a medical device (SaMD) designed t0 treat anxiety and depressive symptoms created by unique psychological stressors specific to adult patients with AML undergoing high-intensity induction chemotherapy (HIC). This digital therapeutic can be used for inpatient setting during the 4-6 weeks related with HIC treatment.

Symptoms are difficult for thousands of patients diagnosed with AML each year. The advancement of innovative therapeutic approaches for the treatment of the associated distress following a diagnosis is promising for patients and addresses an unmet need.

AML is a rare type of bone marrow and blood cancer accounting for one per cent of all cancers. By 2021, it is expected that 20,240 new cases of AML will arise and 11,400 people will be died with this disease.

U.S. Food and Drug Administration (FDA) grants Breakthrough Device Designation for BNT200 for the treatment of Acute Myeloid Leukemia.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024